Brokers Offer Predictions for Viking Therapeutics’ FY2018 Earnings (VKTX)

Viking Therapeutics (NASDAQ:VKTX) – Stock analysts at Zacks Investment Research boosted their FY2018 EPS estimates for shares of Viking Therapeutics in a research report issued on Monday, May 14th. Zacks Investment Research analyst D. Bautz now expects that the biotechnology company will post earnings of ($0.43) per share for the year, up from their previous estimate of ($0.45).

Other equities analysts have also recently issued research reports about the company. ValuEngine upgraded Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. HC Wainwright set a $11.00 price objective on Viking Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 10th. Maxim Group set a $8.00 price objective on Viking Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 10th. William Blair began coverage on Viking Therapeutics in a research note on Monday, April 30th. They issued an “outperform” rating for the company. Finally, BidaskClub cut Viking Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 16th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Viking Therapeutics presently has a consensus rating of “Buy” and an average price target of $9.00.

Shares of Viking Therapeutics opened at $5.31 on Wednesday, according to Marketbeat Ratings. The stock has a market capitalization of $233.27 million, a PE ratio of -6.72 and a beta of 2.10. Viking Therapeutics has a 1 year low of $4.58 and a 1 year high of $4.98.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02.

A number of hedge funds have recently bought and sold shares of the stock. Iguana Healthcare Management LLC lifted its stake in Viking Therapeutics by 66.7% during the first quarter. Iguana Healthcare Management LLC now owns 375,000 shares of the biotechnology company’s stock worth $1,639,000 after purchasing an additional 150,000 shares during the last quarter. Millennium Management LLC lifted its stake in Viking Therapeutics by 99.1% during the first quarter. Millennium Management LLC now owns 1,399,370 shares of the biotechnology company’s stock worth $6,115,000 after purchasing an additional 696,398 shares during the last quarter. Sio Capital Management LLC lifted its stake in Viking Therapeutics by 2.1% during the first quarter. Sio Capital Management LLC now owns 1,276,845 shares of the biotechnology company’s stock worth $5,580,000 after purchasing an additional 26,595 shares during the last quarter. UBS Group AG lifted its stake in Viking Therapeutics by 533.3% during the first quarter. UBS Group AG now owns 63,329 shares of the biotechnology company’s stock worth $277,000 after purchasing an additional 53,329 shares during the last quarter. Finally, Opaleye Management Inc. lifted its stake in Viking Therapeutics by 129.1% during the first quarter. Opaleye Management Inc. now owns 1,100,800 shares of the biotechnology company’s stock worth $4,810,000 after purchasing an additional 620,242 shares during the last quarter. Hedge funds and other institutional investors own 20.21% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply